CNTA's Sharpe Ratio of 3.12 indicates that for each unit of volatility, it generates 3.12 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jul 18, 2026).
Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.
CNTA Sharpe Ratio Market Positioning
The chart shows CNTA's Sharpe Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.
- Red zone (bottom 25%): -0.45 or lower
- Yellow zone (middle 50%): -0.45 to 0.97
- Green zone (top 25%): 0.97 or higher
- Top 1%: 4.37+
- Median: 0.10 — half of all investments score higher
How it compares to other similar stocks
The table compares Centessa Pharmaceuticals Limited's Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how CNTA's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jul 18, 2026.
| Symbol | Name | 1Y Sharpe Ratio | 5Y Sharpe Ratio | 10Y Sharpe Ratio | All Time Sharpe Ratio |
|---|---|---|---|---|---|
| RVMDW | Revolution Medicines Inc. Warrant | 14.47 | |||
| ERAS | Erasca, Inc. | 11.38 | |||
| STTK | Shattuck Labs, Inc. | 8.99 | |||
| SLGL | Sol-Gel Technologies Ltd. | 8.95 | |||
| DRTSW | Alpha Tau Medical Ltd. Warrant | 8.15 | |||
| CLYM | Climb Bio Inc | 7.87 | |||
| SYRE | Spyre Therapeutics Inc. | 7.14 | |||
| ANRO | Alto Neuroscience, Inc | 6.75 | |||
| LQDA | Liquidia Corporation | 6.74 | |||
| RLMD | Relmada Therapeutics, Inc. | 6.62 | |||
| CNTA | Centessa Pharmaceuticals Limited | — |
Loading charts...
How does CNTA fit in your portfolio?
Add your other holdings to see your portfolio's Sharpe Ratio and find out.
Analyze Your Portfolio